Modular Bioprocessing System for Parallel Cell Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing bioprocessing systems for CAR-T cell therapy are cumbersome, prone to contamination, and inflexible, requiring extensive human intervention and resulting in high costs and workflow bottlenecks, while also lacking the ability to efficiently manage parallel processing of multiple samples.
Innovation Solution
A modular bioprocessing system comprising distinct modules for cell enrichment, activation, genetic modification, and expansion, allowing for parallel processing and minimizing human handling through automated fluid management and closed-system operations, enabling efficient scaling and flexibility in manufacturing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If automated systems are utilized to reduce human touchpoints, then contamination risk is reduced, but system cost and inflexibility increase
Solution Approach 1:
The bioprocessing system is divided into multiple independent modules (cell isolation module, activation module, expansion module, harvesting module) that can be independently configured and operated. This segmentation allows automation where needed while maintaining flexibility in other areas, resolving the contradiction between contamination reduction and system cost.
Solution Approach 2:
The system employs universal interfaces and standardized protocols across all modules, allowing a single automated platform to handle multiple cell therapy processes and configurations. This multi-functionality reduces the need for specialized expensive equipment for each specific task, lowering overall system cost while maintaining automation benefits.
2Reliability
If automated systems are utilized to reduce human touchpoints, then contamination risk is reduced, but workflow flexibility decreases
Solution Approach 1:
The system incorporates dynamic control capabilities where processing parameters, flow rates, and module operations can be adjusted in real-time based on process requirements. This dynamic adaptability allows the automated system to handle varying workflows and protocols while maintaining closed-system integrity and reducing contamination risk.
Solution Approach 2:
The system allows for parameter changes in processing conditions (temperature, pressure, flow rates, incubation times) without requiring physical reconfiguration or human intervention. This enables flexible adaptation to different cell therapy protocols while maintaining automated closed-system operation, resolving the contradiction between contamination reduction and workflow flexibility.
3Device complexity
If sequential processing is used, then system complexity is reduced, but production time and bottlenecks increase
Solution Approach 1:
The processing workflow is segmented into independent parallel modules that can simultaneously process multiple samples or different process steps. This modular parallel architecture enables concurrent operations (e.g., cell isolation in one module while activation occurs in another) without increasing overall system complexity, as each module remains independently controllable.
Solution Approach 2:
The system maintains continuous processing through parallel module operation and automated material transfer between modules. Multiple samples can be processed simultaneously through different modules, and the automated fluid management ensures continuous flow of cells and reagents without interruption, eliminating bottlenecks while keeping each module relatively simple.
4Adaptability or versatility
If manual handling is increased to improve flexibility, then adaptability increases, but contamination risk and human intervention increase
Solution Approach 1:
The system incorporates self-service capabilities through automated parameter adjustment, self-regulating flow control, and autonomous module coordination. This allows the system to adapt to different processes automatically without human intervention, maintaining both high adaptability and low contamination risk by eliminating manual handling while preserving process flexibility.
Data Source
AI summary
A bioprocessing system includes a first fluid assembly having a first fluid assembly line connected to a first port of a first bioreactor vessel though a first bioreactor line of a first bioreactor vessel, a second fluid assembly having a second fluid assembly line connected to a second port of the first bioreactor vessel through a second bioreactor line of the first bioreactor vessel, and an interconnect line providing for fluid communication between the first fluid assembly and the second fluid assembly, and for fluid communication between the second bioreactor line of the first bioreactor vessel and the first bioreactor line of the first bioreactor vessel.